APOA4 Protects Chondrocytes and Modulates Wnt Signaling in Osteoarthritis

Area of Science:

• Biochemistry
• Molecular Biology
• Rheumatology

Background:

• Osteoarthritis (OA) pathogenesis is characterized by extracellular matrix (ECM) degradation and inflammation.
• The role of Apolipoprotein A4 (APOA4) in OA remains uncharacterized, despite its known involvement in lipid metabolism.

Purpose of the Study:

• To investigate the role and mechanism of Apolipoprotein A4 (APOA4) in osteoarthritis (OA).
• To determine if APOA4 has chondroprotective effects and explore its potential as a therapeutic target for OA.

Main Methods:

• Analysis of APOA4 expression in clinical OA samples (infrapatellar fat pad, synovial fluid, serum) using immunohistochemistry and ELISA.
• In vitro studies using human chondrocytes treated with recombinant APOA4, siRNA knockdown, or overexpression.
• Functional assays (qPCR, RNA-seq, CCK-8, colony formation) and inflammatory modeling with IL-1β to assess chondrocyte response.
• Investigation of Wnt/β-catenin pathway involvement via Wnt3a rescue experiments.

Main Results:

• APOA4 expression was significantly higher in OA tissues and fluids compared to controls.
• APOA4 treatment increased anabolic markers (COL2, ACAN) and decreased catabolic factors (MMP3, MMP13) in chondrocytes.
• APOA4 attenuated IL-1β-induced inflammation and chondrocyte proliferation was enhanced.
• RNA-seq indicated Wnt/β-catenin pathway suppression by APOA4, which was partially reversed by Wnt3a.

Conclusions:

• APOA4 plays a protective role in OA by promoting ECM anabolism and reducing inflammation.
• APOA4 exerts its effects partly through the suppression of Wnt/β-catenin signaling.
• APOA4 represents a novel therapeutic target for mitigating osteoarthritis progression.